A new Phase 2 trial has been launched to evaluate FG-3246 (FOR46), an antibody-drug conjugate targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC).
The study will enroll 75 patients who have progressed on one prior androgen receptor signaling inhibitor but have not received taxane chemotherapy.
This follows promising Phase 1b results, presented at ASCO 2024, where FG-3246 combined with enzalutamide showed a median radiographic progression-free survival of 10.2 months. The treatment was well-tolerated, with manageable side effects such as fatigue, neutropenia, and peripheral neuropathy. If successful, FG-3246 could offer a new therapeutic option for mCRPC patients who have limited alternatives.
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with mHSPC - July 17, 2024
Update on Prostate Cancer Vaccines from Previous Posts done over the last few years... and a new one...
